Fiche société
The Affiliated Hospital of Qingdao University
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| CD20/BCMA-directed CAR-T cells Autologous 2nd generationThis is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy | Myasthénie | Phase 1 | Immunomodulation + Thérapie cellulaire | China | À vérifier |
| CD20/BCMA-directed CAR-T cells Autologous 2nd generationThis is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy | Myasthénie | Phase 1 | Immunomodulation + Thérapie cellulaire | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| CD20/BCMA-directed CAR-T cells Autologous 2nd generation | Myasthénie | Phase 1 | NCT07676266 | A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy | NOT_YET_RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||